| abstract |
The present disclosure relates to recombinant T cell receptors capable of binding to the gp100 epitope and nucleic acid molecules encoding the same. In some embodiments, the nucleic acid molecule further comprises a second nucleotide sequence, wherein the second nucleotide sequence or a polypeptide encoded by the second nucleotide sequence inhibits expression of an endogenous TCR. Another aspect of the disclosure relates to vectors comprising the nucleic acid molecule and cells comprising the recombinant TCR, nucleic acid molecule, or vector. Another aspect of the present disclosure relates to methods of using the same. In some embodiments, the method comprises treating cancer in a subject in need thereof. |